Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) CarcinomaBusiness Wire • 03/26/26
Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026Business Wire • 03/19/26
Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha • 03/18/26
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United StatesBusiness Wire • 03/11/26
Excellere Partners and GHO Capital Sell Biocare Medical to Agilent TechnologiesGlobeNewsWire • 03/09/26
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology SolutionsBusiness Wire • 03/09/26
Agilent Technologies, Inc. (A) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Investing in Agilent (A)? Don't Miss Assessing Its International Revenue TrendsZacks Investment Research • 03/02/26
Stay Ahead of the Game With Agilent (A) Q1 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 02/20/26
Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact AwardBusiness Wire • 02/11/26
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)Business Wire • 02/11/26